Paysign Q1 2026 revenue $28.04M (+50.8% YoY); pharma up 81.9%, net income $5.44M

Paysign, Inc.

Revenue $28.04M, up 50.8% YoY; pharma $15.68M (+81.9%), plasma $11.75M (+24.9%).
Net income $5.44M ($0.09 diluted EPS) vs $2.59M ($0.05); adj. EBITDA $10.59M, up 113.4%.
Operating margin 23.8% vs 13.4% YoY; gross margin 65.0% from 62.9% on pharma mix shift.
Active patient affordability programs 135 (net +45 in 12 months); plasma centers 573 (net +89).
Q2 2026 guidance: revenue $26.2M-$26.7M; full-year revenue $106.5M-$110.5M, net income $13M-$16M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Paysign, Inc. reported first quarter 2026 results: revenue $28.04 million, net income $5.44 million, or $0.09 per diluted share, EPS $0.09 per diluted share.

Period: first quarter 2026
Revenue: $28.04 million
Net income: $5.44 million, or $0.09 per diluted share
EPS: $0.09 per diluted share
Result: reported results

Exact text from the filing

for the life sciences industries, today announced financial results for the first quarter 2026. First Quarter 2026 Financial Highlights · First quarter 2026 revenues of $28.04 million, up 50.8% from f irst quarter 2025 · First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus f irst quarter 2025; added 45 net patient

View on SEC.gov

Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.